What benefit–risk trade-offs are acceptable to rheumatoid arthritis patients during treatment selection? Evidence from a multicountry choice experiment
Authors' conclusion
Treatment preferences of patients with RA were individual-specific, but driven by benefits and risks, with no single attribute dominating the decision-making.
Study context
- Population
- Patients with rheumatoid arthritis (RA) aged ≥18 years receiving systemic DMARD therapy, residents of Europe or USA42% female
- Participants
- 2,090 patients
- Outcome
- Trade-offs patients with RA were willing to make during treatment selection (preferences for treatment attributes)
Methodological detailsonline, multicountry, correlated mixed logit model, male patients oversampled for subgroup analyses
- Online
- Multicountry
- Correlated mixed logit model
- Male patients oversampled for subgroup analyses
Main finding
As reported in the abstract
Treatment attribute preferences
- Estimated effects significant for all attributes but varied between patients
- p<0.001
- Different priorities between males and females in average relative attribute importance
- p<0.001
- Patients aged 18-44 years placed less importance on frequency and mode of administration than older age groups
- p<0.05
- Willing to accept higher risk of serious infections and blood clots for improvements in pain, daily activities or administration convenience; acceptable trade-offs varied between patients
- p<0.05
Original publication
What benefit–risk trade-offs are acceptable to rheumatoid arthritis patients during treatment selection? Evidence from a multicountry choice experiment. RMD Open. Published 9 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →